498 related articles for article (PubMed ID: 28515346)
1. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.
Tian Y; Li M; Yu C; Zhang R; Zhang X; Huang R; Lu L; Yuan F; Fan Y; Zhou B; Men K; Xu H; Yang L
Oncotarget; 2017 Jul; 8(28):45951-45964. PubMed ID: 28515346
[TBL] [Abstract][Full Text] [Related]
2. Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2.
Li M; Shi H; Mu Y; Luo Z; Zhang H; Wan Y; Zhang D; Lu L; Men K; Tian Y; Wu X; Liu X; Pan Y; Fan Y; Yu C; Zhou B; Xiang R; Chen X; Yang L
Mol Cancer; 2014 Jul; 13():179. PubMed ID: 25070035
[TBL] [Abstract][Full Text] [Related]
3. NY-ESO-1 Protein Vaccine Combining Alum, CpG ODN, and HH2 Complex Adjuvant Induces Protective and Therapeutic Anti-Tumor Responses in Murine Multiple Myeloma.
Wang H; Huang W; Gao H; Liu TT
Onco Targets Ther; 2020; 13():8069-8077. PubMed ID: 32884292
[TBL] [Abstract][Full Text] [Related]
4. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
[TBL] [Abstract][Full Text] [Related]
5. CpG oligodeoxynucleotide synergizes innate defense regulator peptide for enhancing the systemic and mucosal immune responses to pseudorabies attenuated virus vaccine in piglets in vivo.
Cao D; Li H; Jiang Z; Cheng Q; Yang Z; Xu C; Cao G; Zhang L
Int Immunopharmacol; 2011 Jun; 11(6):748-54. PubMed ID: 21310256
[TBL] [Abstract][Full Text] [Related]
6. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN.
Mansourian M; Badiee A; Jalali SA; Shariat S; Yazdani M; Amin M; Jaafari MR
Immunol Lett; 2014 Nov; 162(1 Pt A):87-93. PubMed ID: 25086399
[TBL] [Abstract][Full Text] [Related]
7. A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine.
Sugai T; Mori M; Nakazawa M; Ichino M; Naruto T; Kobayashi N; Kobayashi Y; Minami M; Yokota S
Vaccine; 2005 Nov; 23(46-47):5450-6. PubMed ID: 16006019
[TBL] [Abstract][Full Text] [Related]
8. Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4
Chiodetti AL; Sánchez Vallecillo MF; Dolina JS; Crespo MI; Marin C; Schoenberger SP; Allemandi DA; Palma SD; Pistoresi-Palencia MC; Morón G; Maletto BA
Front Immunol; 2018; 9():2319. PubMed ID: 30364187
[TBL] [Abstract][Full Text] [Related]
9. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
10. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
11. Innate defense regulator peptide synergizes with CpG ODN for enhanced innate intestinal immune responses in neonate piglets.
Yang J; Mao M; Zhang S; Li H; Jiang Z; Cao G; Cao D; Wang X; Zhang L
Int Immunopharmacol; 2012 Feb; 12(2):415-24. PubMed ID: 22226751
[TBL] [Abstract][Full Text] [Related]
12. Synthetic innate defence regulator peptide enhances in vivo immunostimulatory effects of CpG-ODN in newborn piglets.
Cao D; Li H; Jiang Z; Xu C; Cheng Q; Yang Z; Cao G; Zhang L
Vaccine; 2010 Aug; 28(37):6006-13. PubMed ID: 20637306
[TBL] [Abstract][Full Text] [Related]
13. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
[TBL] [Abstract][Full Text] [Related]
14. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.
McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
FEMS Immunol Med Microbiol; 2002 Feb; 32(3):179-85. PubMed ID: 11934561
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity.
Stern BV; Boehm BO; Tary-Lehmann M
J Immunol; 2002 Jun; 168(12):6099-105. PubMed ID: 12055220
[TBL] [Abstract][Full Text] [Related]
16. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
17. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
[TBL] [Abstract][Full Text] [Related]
18. Heterologous administration of HPV16 E7 epitope-loaded nanocomplexes inhibits tumor growth in mouse model.
Goradel NH; Negahdari B; Mohajel N; Malekshahi ZV; Shirazi MMA; Arashkia A
Int Immunopharmacol; 2021 Dec; 101(Pt B):108298. PubMed ID: 34739928
[TBL] [Abstract][Full Text] [Related]
19. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity.
Kindrachuk J; Jenssen H; Elliott M; Townsend R; Nijnik A; Lee SF; Gerdts V; Babiuk LA; Halperin SA; Hancock RE
Vaccine; 2009 Jul; 27(34):4662-71. PubMed ID: 19539585
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.
Woo SJ; Kim CH; Park MY; Kim HS; Sohn HJ; Park JS; Kim HJ; Oh ST; Kim TG
Cancer Sci; 2008 May; 99(5):1034-9. PubMed ID: 18294279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
